The Cross-Border Biotech Blog

Biotechnology, Health and Business in Canada, the United States and Worldwide

Tag Archives: Intervet

Merck and Schering-Plough in Canada

Following this morning’s announcement of Merck’s offer for Schering-Plough (0.5767 share of Merck and $10.50 in cash for each Schering-Plough share = $23.61 a share, a 34% premium, with Merck shareholders owning 68% of the combined company), we thought we’d take a look at the respective Canadian operations.  See what we turned up after the jump…

Follow

Get every new post delivered to your Inbox.

Join 126 other followers